TDI01 / Graviton Biosci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TDI01 / Graviton Biosci
NCT06102083: A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

Not yet recruiting
2
120
NA
TDI01 suspension
Beijing Tide Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
08/25
03/26
NCT06169722: TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

Recruiting
1/2
120
RoW
TDI01 suspension
Beijing Tide Pharmaceutical Co., Ltd
GVHD, Chronic
02/25
08/27
ChiCTR2200058868: Safety, tolerability, and drug administration of the suspension in single/multiple doses in Chinese healthy subjects Phase I clinical study of TDI01 kinetic characteristics and food effects

Not yet recruiting
1
62
 
Single dose study ;Food impact research ;multiple dose study
Chinese PLA General Hospital; Chinese PLA General Hospital, sponser
Idiopathic pulmonary fibrosis
 
 
ChiCTR2300071134: A drug interaction study evaluating TDI01 suspension with omeprazole enteric-coated capsules in healthy subjects

Not yet recruiting
1
24
 
D1 to D2: 40mg omeprazole enteric coated capsules orally on an empty stomach; 400mg TDI01 suspension orally on an empty stomach from D3 to D7; and 40mg omeprazole enteric coated capsules and 400mg TDI01 suspension orally on an empty stomach at D7
Chinese PLA General Hospital; Chinese PLA General Hospital, TIDE pharmaceutical
Idiopathic pulmonary fibrosis
 
 
ChiCTR2400082056: An exploratory clinical trial to evaluate the safety and efficacy of TDI01 suspension in the patients with hepatic fibrosis

Recruiting
N/A
12
 
TDI01 200mg QD ; TDI01 400mg QD
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self-raised
Hepatic fibrosis
 
 

Download Options